Sage Journals: Discover world-class research

Abstract

Objectives

Arteriovenous graft for hemodialysis shows poorer outcomes than arteriovenous fistula, due to frequent stenosis and thrombosis. We investigated arteriovenous graft patency outcomes and prognostic factors for these outcomes.

Methods

We included a single-center cohort of patients receiving arteriovenous graft for hemodialysis access from 2010 to 2014. Demographics, laboratory data, comorbidities, and medications were collected from medical records. Surgical factors related to graft operation including the type and diameter of connected vessels, graft location, and type of operation (elective or emergency) were also recorded. Outcomes included primary and secondary patency. Survival analysis was conducted using the Kaplan-Meier method; univariate and multivariate analyses were used to evaluate the prognostic factors.

Results

Data from 225 grafts were analyzed. During the follow-up period (mean: 583 days, range: 1–1717 days), 138 (61%) grafts required intervention and 46 (20%) permanently failed. Primary patency at one, two, and three years was 42%, 20%, and 16%, respectively. Secondary patency at one, two, and three years was 85%, 72%, and 64%, respectively. Multivariate analysis showed that primary patency was negatively associated with increasing age and location of vessel anastomosis (reference-brachiobrachial anastomosis; brachiobasilic – HR, 0.569; 95% CI, 0.376–0.860; p = 0.007; brachioaxillary anastomosis – HR 0.407; 95% CI, 0.263–0.631; p < 0.0001); secondary patency was positively associated with diastolic blood pressure, serum albumin level, and hemoglobin over 10 g/dL. Adverse events other than stenosis or thrombosis, such as infection/inflammation or pseudoaneurysm were observed in approximately 20% of grafts.

Conclusions

Factors associated with diminished primary arteriovenous graft patency included increased patient age and location of vessel anastomosis (brachiobrachial type compared to brachiobasilic or brachioaxillary type); diminished secondary patency was associated with low diastolic blood pressure, low serum albumin, and hemoglobin level under 10 g/dL. Among these factors, diastolic blood pressure, serum albumin, and hemoglobin level may be modifiable and could improve arteriovenous graft patency outcomes.

Keywords

Arteriovenous graft hemodialysis access patency outcome primary patency secondary patency

Get full access to this article

View all access options for this article.

References

III. NKF-K/DOQI clinical practice guidelines for vascular access: update 2000. Am J Kidney Dis 2001; 37: S137–S181.

Woo

Goldman

Romley

JA.

Early failure of dialysis access among the elderly in the era of fistula first. Clin J Am Soc Nephrol 2015; 10: 1791–1798.

Huber

Carter

et al . Patency of autogenous and polytetrafluoroethylene upper extremity arteriovenous hemodialysis accesses: a systematic review. J Vasc Surg 2003; 38: 1005–1011.

Sidawy

Gray

Besarab

et al . Recommended standards for reports dealing with arteriovenous hemodialysis accesses. J Vasc Surg 2002; 35: 603–610.

Al-Jaishi

Oliver

Thomas

et al . Patency rates of the arteriovenous fistula for hemodialysis: a systematic review and meta-analysis. Am J Kidney Dis 2014; 63: 464–478.

Suemitsu

Iida

Shiraki

et al . Predicting loss of patency after forearm loop arteriovenous graft. J Vasc Surg 2016; 64: 395–401.

Smith

Gohil

Chetter

IC.

Factors affecting the patency of arteriovenous fistulas for dialysis access. J Vasc Surg 2012; 55: 849–855.

Konner

Hulbert-Shearon

Roys

et al . Tailoring the initial vascular access for dialysis patients. Kidney Int 2002; 62: 329–338.

Davoudi

Tayebi

Beheshtian

Primary patency time of basilic vein transposition versus prosthetic brachioaxillary access grafts in hemodialysis patients. J Vasc Access 2013; 14: 111–115.

10.

Weale

Bevis

Neary

et al . A comparison between transposed brachiobasilic arteriovenous fistulas and prosthetic brachioaxillary access grafts for vascular access for hemodialysis. J Vasc Surg 2007; 46: 997–1004.

11.

Tanner

da Silva

AF.

Medical adjuvant treatment to improve the patency of arteriovenous fistulae and grafts: a systematic review and meta-analysis. Eur J Vasc Endovasc Surg 2016; 52: 243–252.

12.

Grontoft

Mulec

Gutierrez

et al . Thromboprophylactic effect of ticlopidine in arteriovenous fistulas for haemodialysis. Scand J Urol Nephrol 1985; 19: 55–57.

13.

Fiskerstrand

Thompson

Burnet

et al . Double-blind randomized trial of the effect of ticlopidine in arteriovenous fistulas for hemodialysis. Artif Organs 1985; 9: 61–63.

14.

Grontoft

Larsson

Mulec

et al . Effects of ticlopidine in AV-fistula surgery in uremia. Fistula Study Group. Scand J Urol Nephrol 1998; 32: 276–283.

15.

Crowther

Clase

Margetts

et al . Low-intensity warfarin is ineffective for the prevention of PTFE graft failure in patients on hemodialysis: a randomized controlled trial. J Am Soc Nephrol 2002; 13: 2331–2337.

Arteriovenous graft patency outcomes and prognostic factors